Selected research
Industry Growth & Trends
Global Biomarker Clinical Phase Outsourcing Services Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Biomarker Clinical Phase Outsourcing Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Biomarker Clinical Phase Outsourcing Services is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Biomarker Clinical Phase Outsourcing Services is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Biomarker Clinical Phase Outsourcing Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Biomarker Clinical Phase Outsourcing Services market include ICON plc, Fujirebio lnc, Charles River Laboratories International,Inc., Laboratory Corporation of America Holdings, Parexel lnternational Corporation, Proteome Sciences plc, Eurofins Scientific, Wuxi AppTec Co., Ltd. and NorthEast BioAnalytical Laboratories LLC., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Biomarker Clinical Phase Outsourcing Services market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Biomarker Clinical Phase Outsourcing Services market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Biomarker Clinical Phase Outsourcing Services market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Biomarker Clinical Phase Outsourcing Services.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Biomarker Clinical Phase Outsourcing Services market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Biomarker Clinical Phase Outsourcing Services Market by Company
ICON plc
Fujirebio lnc
Charles River Laboratories International,Inc.
Laboratory Corporation of America Holdings
Parexel lnternational Corporation
Proteome Sciences plc
Eurofins Scientific
Wuxi AppTec Co., Ltd.
NorthEast BioAnalytical Laboratories LLC.
Celerion, Inc.
GenScript ProBio Co.,Ltd.
Biomarker Clinical Phase Outsourcing Services Segment by Type
Predictive Biomarker
Prognostic Biomarker
Safety Biomarker
Surrogate Endpoints
Biomarker Clinical Phase Outsourcing Services Segment by Application
Pharmaceutical Companies
Biotechnology Companies
Others
Biomarker Clinical Phase Outsourcing Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biomarker Clinical Phase Outsourcing Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biomarker Clinical Phase Outsourcing Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biomarker Clinical Phase Outsourcing Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Biomarker Clinical Phase Outsourcing Services companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Predictive Biomarker
- Prognostic Biomarker
- Safety Biomarker
- Surrogate Endpoints
Applications
- Pharmaceutical Companies
- Biotechnology Companies
- Others
Companies covered
- ICON plc
- Fujirebio lnc
- Charles River Laboratories International,Inc.
- Laboratory Corporation of America Holdings
- Parexel lnternational Corporation
- Proteome Sciences plc
- Eurofins Scientific
- Wuxi AppTec Co., Ltd.
- NorthEast BioAnalytical Laboratories LLC.
- Celerion, Inc.
- GenScript ProBio Co.,Ltd.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Biomarker Clinical Phase Outsourcing Services Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Biomarker Clinical Phase Outsourcing Services Market Size by Region (2021-2032)
- 1.4.1 Global Biomarker Clinical Phase Outsourcing Services Market Size by Region (2021-2026)
- 1.4.2 Global Biomarker Clinical Phase Outsourcing Services Market Size by Region (2027-2032)
- 1.5 Key Regions Biomarker Clinical Phase Outsourcing Services Market Size (2021-2032)
- 1.5.1 North America Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate (2021-2032)
- 1.5.4 South America Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate (2021-2032)
2 Biomarker Clinical Phase Outsourcing Services Market by Type
- 2.1 Type Introduction
- 2.1.1 Predictive Biomarker
- 2.1.2 Prognostic Biomarker
- 2.1.3 Safety Biomarker
- 2.1.4 Surrogate Endpoints
- 2.2 Global Biomarker Clinical Phase Outsourcing Services Market Size by Type
- 2.2.1 Global Biomarker Clinical Phase Outsourcing Services Market Size Overview by Type (2021-2032)
- 2.2.2 Global Biomarker Clinical Phase Outsourcing Services Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Biomarker Clinical Phase Outsourcing Services Market Size Forecasted by Type (2027-2032)
- 2.3 Global Biomarker Clinical Phase Outsourcing Services Market Size by Regions
- 2.3.1 North America Biomarker Clinical Phase Outsourcing Services Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Biomarker Clinical Phase Outsourcing Services Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Biomarker Clinical Phase Outsourcing Services Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Biomarker Clinical Phase Outsourcing Services Market Size Breakdown by Type (2021-2026)
3 Biomarker Clinical Phase Outsourcing Services Market by Application
- 3.1 Type Introduction
- 3.1.1 Pharmaceutical Companies
- 3.1.2 Biotechnology Companies
- 3.1.3 Others
- 3.2 Global Biomarker Clinical Phase Outsourcing Services Market Size by Application
- 3.2.1 Global Biomarker Clinical Phase Outsourcing Services Market Size Overview by Application (2021-2032)
- 3.2.2 Global Biomarker Clinical Phase Outsourcing Services Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Biomarker Clinical Phase Outsourcing Services Market Size Forecasted by Application (2027-2032)
- 3.3 Global Biomarker Clinical Phase Outsourcing Services Market Size by Regions
- 3.3.1 North America Biomarker Clinical Phase Outsourcing Services Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Biomarker Clinical Phase Outsourcing Services Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Biomarker Clinical Phase Outsourcing Services Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Biomarker Clinical Phase Outsourcing Services Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Biomarker Clinical Phase Outsourcing Services Industry Trends
- 4.2 Biomarker Clinical Phase Outsourcing Services Industry Drivers
- 4.3 Biomarker Clinical Phase Outsourcing Services Industry Opportunities and Challenges
- 4.4 Biomarker Clinical Phase Outsourcing Services Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Biomarker Clinical Phase Outsourcing Services Revenue (2021-2026)
- 5.2 Global Biomarker Clinical Phase Outsourcing Services Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Biomarker Clinical Phase Outsourcing Services Key Company Headquarters & Area Served
- 5.4 Global Biomarker Clinical Phase Outsourcing Services Company, Product Type & Application
- 5.5 Global Biomarker Clinical Phase Outsourcing Services Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Biomarker Clinical Phase Outsourcing Services Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Biomarker Clinical Phase Outsourcing Services Players Market Share by Revenue in 2025
- 5.6.3 2025 Biomarker Clinical Phase Outsourcing Services Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 ICON plc
- 6.1.1 ICON plc Company Information
- 6.1.2 ICON plc Business Overview
- 6.1.3 ICON plc Biomarker Clinical Phase Outsourcing Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 ICON plc Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 6.1.5 ICON plc Recent Developments
- 6.2 Fujirebio lnc
- 6.2.1 Fujirebio lnc Company Information
- 6.2.2 Fujirebio lnc Business Overview
- 6.2.3 Fujirebio lnc Biomarker Clinical Phase Outsourcing Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Fujirebio lnc Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 6.2.5 Fujirebio lnc Recent Developments
- 6.3 Charles River Laboratories International,Inc.
- 6.3.1 Charles River Laboratories International,Inc. Company Information
- 6.3.2 Charles River Laboratories International,Inc. Business Overview
- 6.3.3 Charles River Laboratories International,Inc. Biomarker Clinical Phase Outsourcing Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Charles River Laboratories International,Inc. Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 6.3.5 Charles River Laboratories International,Inc. Recent Developments
- 6.4 Laboratory Corporation of America Holdings
- 6.4.1 Laboratory Corporation of America Holdings Company Information
- 6.4.2 Laboratory Corporation of America Holdings Business Overview
- 6.4.3 Laboratory Corporation of America Holdings Biomarker Clinical Phase Outsourcing Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Laboratory Corporation of America Holdings Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 6.4.5 Laboratory Corporation of America Holdings Recent Developments
- 6.5 Parexel lnternational Corporation
- 6.5.1 Parexel lnternational Corporation Company Information
- 6.5.2 Parexel lnternational Corporation Business Overview
- 6.5.3 Parexel lnternational Corporation Biomarker Clinical Phase Outsourcing Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Parexel lnternational Corporation Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 6.5.5 Parexel lnternational Corporation Recent Developments
- 6.6 Proteome Sciences plc
- 6.6.1 Proteome Sciences plc Company Information
- 6.6.2 Proteome Sciences plc Business Overview
- 6.6.3 Proteome Sciences plc Biomarker Clinical Phase Outsourcing Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Proteome Sciences plc Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 6.6.5 Proteome Sciences plc Recent Developments
- 6.7 Eurofins Scientific
- 6.7.1 Eurofins Scientific Company Information
- 6.7.2 Eurofins Scientific Business Overview
- 6.7.3 Eurofins Scientific Biomarker Clinical Phase Outsourcing Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Eurofins Scientific Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 6.7.5 Eurofins Scientific Recent Developments
- 6.8 Wuxi AppTec Co., Ltd.
- 6.8.1 Wuxi AppTec Co., Ltd. Company Information
- 6.8.2 Wuxi AppTec Co., Ltd. Business Overview
- 6.8.3 Wuxi AppTec Co., Ltd. Biomarker Clinical Phase Outsourcing Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Wuxi AppTec Co., Ltd. Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 6.8.5 Wuxi AppTec Co., Ltd. Recent Developments
- 6.9 NorthEast BioAnalytical Laboratories LLC.
- 6.9.1 NorthEast BioAnalytical Laboratories LLC. Company Information
- 6.9.2 NorthEast BioAnalytical Laboratories LLC. Business Overview
- 6.9.3 NorthEast BioAnalytical Laboratories LLC. Biomarker Clinical Phase Outsourcing Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 NorthEast BioAnalytical Laboratories LLC. Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 6.9.5 NorthEast BioAnalytical Laboratories LLC. Recent Developments
- 6.10 Celerion, Inc.
- 6.10.1 Celerion, Inc. Company Information
- 6.10.2 Celerion, Inc. Business Overview
- 6.10.3 Celerion, Inc. Biomarker Clinical Phase Outsourcing Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Celerion, Inc. Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 6.10.5 Celerion, Inc. Recent Developments
- 6.11 GenScript ProBio Co.,Ltd.
- 6.11.1 GenScript ProBio Co.,Ltd. Company Information
- 6.11.2 GenScript ProBio Co.,Ltd. Business Overview
- 6.11.3 GenScript ProBio Co.,Ltd. Biomarker Clinical Phase Outsourcing Services Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 GenScript ProBio Co.,Ltd. Biomarker Clinical Phase Outsourcing Services Product Portfolio
- 6.11.5 GenScript ProBio Co.,Ltd. Recent Developments
7 North America
- 7.1 North America Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Biomarker Clinical Phase Outsourcing Services Market Size by Country (2021-2026)
- 7.3 North America Biomarker Clinical Phase Outsourcing Services Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Biomarker Clinical Phase Outsourcing Services Market Size by Country (2021-2026)
- 8.3 Europe Biomarker Clinical Phase Outsourcing Services Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Biomarker Clinical Phase Outsourcing Services Market Size by Country (2021-2026)
- 10.3 South America Biomarker Clinical Phase Outsourcing Services Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst